Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma

NCT04578600 is registered in ClinicalTrials.gov with Joseph Tuscano as lead sponsor.

NCT NCT04578600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04578600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma
Lead sponsor
Joseph Tuscano
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2020
Completion date
February 21, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

indolent b-cell non-hodgkin lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent chronic lymphocytic leukemia, recurrent follicular lymphoma, recurrent hairy cell leukemia, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mucosa-associated lymphoid tissue lymphoma, recurrent small lymphocytic lymphoma, refractory b-cell non-hodgkin lymphoma, refractory chronic lymphocytic leukemia, refractory follicular lymphoma, refractory hairy cell leukemia, refractory lymphoplasmacytic lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory mucosa-associated lymphoid tissue lymphoma, refractory small lymphocytic lymphoma